BOULDER, Colo.--(BUSINESS WIRE)--Inscripta, Inc., the digital genome engineering company, today announced the appointment of Sri Kosaraju as President and CEO. Kosaraju succeeds Kevin Ness.
Kosaraju currently serves on the Board of Directors and is the Chair of the Audit Committee of 10x Genomics (NASDAQ: TXG) and is on the Board of the non-profit Testing for America. Prior to joining Inscripta, Kosaraju was President of Penumbra (NYSE: PEN), an innovative medical devices company, which he joined prior to their initial public offering as CFO in May 2015. During his tenure, Penumbra experienced rapid growth with revenues increasing from $125 million to $547 million. Earlier, Kosaraju spent 16 years at J.P. Morgan, where he was most recently Head of Healthcare Equity Capital Markets and Co-Head of Technology Equity Capital Markets. While at J.P. Morgan, he worked closely with and advised many emerging, high-growth life science and tech companies. He holds a B.S. from the Massachusetts Institute of Technology.
“On behalf of the Inscripta Board of Directors, we are excited to welcome Sri, an exceptional leader with whom I have worked closely for many years,” said John Stuelpnagel, Chairman of the Board. “In the same manner that Illumina revolutionized DNA sequencing over the last 10 years, we are excited for the automated, multiplexed, industrial-scale Onyx platform to revolutionize gene editing and genome engineering.”
“I am honored to join the talented team at Inscripta,” said Kosaraju. “I am impressed by the people and the transformational digital genome engineering technology. I am excited to see the significant positive impact that this breakthrough technology can have across diverse applications and industries including bio-industrial materials development and manufacturing, genome discovery, healthcare, and sustainability.”
Kosaraju succeeds Kevin Ness, who has led the company since 2016 and will remain as an advisor. “I am proud of our team and their development of the innovative Onyx digital genome engineering platform. I welcome Sri to the team as we ramp up commercial efforts and I remain a strong supporter of this amazing company,” said Ness, former CEO of Inscripta.
About Inscripta
Inscripta is developing the world’s first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at unprecedented scale. Inscripta’s goal is to empower scientists whose gene editing research is stifled by current technical and licensing limitations. The company enables scientists to realize a new era of biological discovery. Inscripta is headquartered in Boulder, Colo., with offices in Pleasanton, Calif., and San Diego. For more information, visit www.inscripta.com.
